
Keywords: Biologic agents; adverse effect; infection; autoimmunity; paradoxical inflammation; ANA; Antinuclear antibody; AS; Ankylosing spondylitis; DMARD; Disease-modifying antirheumatic drug; IBD; Inflammatory bowel disease; ILD; Interstitial lung disease; NTM; N